Amgen Inc.

NasdaqGS:AMGN Rapport sur les actions

Capitalisation boursière : US$162.0b

Amgen Croissance future

Future contrôle des critères 3/6

Amgen devrait augmenter ses bénéfices et son chiffre d'affaires de 19.1% et de 2.4% par an respectivement. Le BPA devrait croître de de 19.6% par an. Le rendement des capitaux propres devrait être 205.5% dans 3 ans.

Informations clés

19.1%

Taux de croissance des bénéfices

19.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices27.4%
Taux de croissance des recettes2.4%
Rendement futur des capitaux propres205.5%
Couverture par les analystes

Good

Dernière mise à jour14 Nov 2024

Mises à jour récentes de la croissance future

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 02
Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Aug 09
Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Recent updates

Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit

Nov 08
Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit

Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market

Nov 03

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 02
Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List

Oct 25

Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms

Sep 26

Amgen: Growth Is Still A Better Choice

Aug 28

Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Aug 09
Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Amgen: Shows Why Dividend Investing Is Getting Tougher

Aug 07

Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt

Jul 26
Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Amgen Inc. (NASDAQ:AMGN)

Jul 11
The Price Is Right For Amgen Inc. (NASDAQ:AMGN)

Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum

Jul 05

Amgen: You Haven't Seen Anything Yet

Jun 17

Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card

Jun 04

Amgen Stock: Poised To Break Out (Technical Analysis)

May 21

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?

May 04
Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?

Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet

May 01

Amgen: The Giant With An Impressive Pipeline

Apr 15

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Apr 01
Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Mar 31

Amgen Will Benefit From Increased Medical Spending

Mar 12

Amgen: A Good Dividend Growth Stock For The Watch List

Mar 04

Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Feb 21
Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Feb 16
Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

Feb 08

Amgen: Accelerating The Business And Dividend Growth

Jan 29

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Jan 29
Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Jan 22

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Dec 28
Is Amgen (NASDAQ:AMGN) A Risky Investment?

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Dec 13
Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Oct 23
Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:AMGN - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202634,8977,60713,53813,87824
12/31/202534,2806,52912,29113,04628
12/31/202433,1794,79411,99012,96427
9/30/202432,5344,2306,2837,257N/A
6/30/202430,9343,1305,4816,446N/A
3/31/202429,5323,7637,0988,096N/A
12/31/202328,1906,7177,3598,471N/A
9/30/202326,8337,5669,37910,582N/A
6/30/202326,5827,9799,68510,800N/A
3/31/202326,1907,9177,5318,621N/A
12/31/202226,3236,5528,7859,721N/A
9/30/202226,3306,8358,9979,880N/A
6/30/202226,3846,5768,3559,320N/A
3/31/202226,3165,7238,4179,321N/A
12/31/202125,9795,8938,3819,261N/A
9/30/202125,7675,6097,8408,606N/A
6/30/202125,4845,7468,8979,556N/A
3/31/202125,1647,0859,83510,467N/A
12/31/202025,4247,2649,88910,497N/A
9/30/202024,9877,35210,23510,858N/A
6/30/202024,3017,29910,20910,867N/A
3/31/202023,9667,6758,7959,439N/A
12/31/201923,3627,8428,5329,150N/A
9/30/201923,3958,0679,1759,830N/A
6/30/201923,5627,9589,0709,726N/A
3/31/201923,7508,0759,71510,414N/A
12/31/201823,7478,39410,55811,296N/A
9/30/201823,3192,20210,44811,114N/A
6/30/201823,1882,364N/A11,295N/A
3/31/201822,9392,219N/A11,519N/A
12/31/201722,8491,979N/A11,177N/A
9/30/201723,0128,178N/A11,265N/A
6/30/201723,0508,174N/A10,473N/A
3/31/201722,9287,893N/A10,824N/A
12/31/201622,9917,722N/A10,354N/A
9/30/201622,5627,587N/A9,327N/A
6/30/201622,4747,433N/A9,557N/A
3/31/201622,1567,216N/A10,164N/A
12/31/201521,6626,939N/A9,731N/A
9/30/201521,4576,433N/A10,103N/A
6/30/201520,7655,814N/A9,952N/A
3/31/201520,5755,708N/A8,895N/A
12/31/201420,0635,158N/A8,952N/A
9/30/201419,7434,885N/A7,945N/A
6/30/201419,4605,009N/A7,011N/A
3/31/201418,9594,720N/A6,384N/A
12/31/201318,6765,081N/A6,291N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de AMGN ( 19.1% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de AMGN ( 19.1% par an) devraient croître plus rapidement que le marché US ( 15.5% par an).

Croissance élevée des bénéfices: Les bénéfices de AMGN devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de AMGN ( 2.4% par an) devrait croître plus lentement que le marché de US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de AMGN ( 2.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de AMGN devrait être très élevé dans 3 ans ( 205.5 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y